Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
BeovuⓇ - Anti-VEGF
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03386474 (CRTH258A2301E1)
Neovascular age-related macular degeneration (nAMD)
Phase 3
NCT04005352 TALON (CRTH258A2303)
Neovascular Age-related Macular Degeneration (nAMD)
Phase 3B
150
Number of treatment-emergent adverse events
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2 mg/50 μL
Patients with neovascular age-related macular degeneration who have completed
the CRTH258A2301 study
Average change in Best-corrected visual acuity
Distribution of the last interval with no disease activity (in a Treat-to-Control
regimen)
Arm 1: Brolucizumab 6 mg intravitreal injection
Arm 2: Aflibercept 2 mg intravitreal injection
Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not
previously received anti-VEGF (vascular endothelial growth factor) treatment
Target Patients
Read-out Milestone(s)
2018 (actual)
Publication
Manuscript submitted
104 Investor Relations | Q4 2021 Results
2022
TBD
NOVARTIS | Reimagining MedicineView entire presentation